A study to explore the efficacy of PTR-36 in adult patients with asthma
Phase 2
- Conditions
- asthma
- Registration Number
- jRCT2080222805
- Lead Sponsor
- TEIJIN PHARMA LIMITED
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- Asthma patients receiving a moderate-dose ICS or a moderate-dose ICS/long-acting beta2-agonist(LABA)combination therapy for more than 4 weeks
- FEV1 >=60% and =<90% of the predicted normal value at randomization
Exclusion Criteria
- BMI >= 30
- smoking history > 10 pack year
- diagnosed with COPD
Study & Design
- Study Type
- Interventional
- Study Design
- Randomized, double-blind, placebo-controlled, multi-center, parallel-group
- Primary Outcome Measures
Name Time Method - Changes in mPEF from time of randomization to final evaluation
- Secondary Outcome Measures
Name Time Method